Zofia Mazerska

List of Publications by Year
in descending order

63	917	516561 16	580701 25
papers	citations	h-index	g-index

68	68	68	1218
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The role of glucuronidation in drug resistance. , 2016, 159, 35-55.		75
2	The impact of lipophilicity on environmental processes, drug delivery and bioavailability of food components. Microchemical Journal, 2019, 146, 393-406.	2.3	67
3	Molecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor drug, C-1311. Biochemical Pharmacology, 2003, 66, 1727-1736.	2.0	38
4	Electroanalytical and spectroscopic procedures for examination of interactions between double stranded DNA and intercalating drugs. Analytical and Bioanalytical Chemistry, 2007, 389, 1931-1940.	1.9	38
5	State of the art and prospects of methods for determination of lipophilicity of chemical compounds. TrAC - Trends in Analytical Chemistry, 2019, 113, 54-73.	5.8	37
6	Progress in Targeting Tumor Cells by Using Drug-Magnetic Nanoparticles Conjugate. Biomacromolecules, 2013, 14, 828-833.	2.6	36
7	Improved cytotoxicity and preserved level of cell death induced in colon cancer cells by doxorubicin after its conjugation with iron-oxide magnetic nanoparticles. Toxicology in Vitro, 2016, 33, 45-53.	1.1	36
8	Products of Metabolic Activation of the Antitumor Drug Ledakrin (Nitracrine) in Vitro. Chemical Research in Toxicology, 2001, 14, 1-10.	1.7	33
9	Enzymatic activation of a new antitumour drug, 5-diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNA. Biochemical Pharmacology, 2001, 61, 685-694.	2.0	32
10	New Unsymmetrical Bisacridine Derivatives Noncovalently Attached to Quaternary Quantum Dots Improve Cancer Therapy by Enhancing Cytotoxicity toward Cancer Cells and Protecting Normal Cells. ACS Applied Materials & Interfaces, 2020, 12, 17276-17289.	4.0	29
11	The Imidazoacridinone Antitumor Drug, C-1311, Is Metabolized by Flavin Monooxygenases but Not by Cytochrome P450s. Drug Metabolism and Disposition, 2011, 39, 1423-1432.	1.7	22
12	Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia. Biochemical Pharmacology, 2013, 86, 231-241.	2.0	21
13	Revision of Biological Methods for Determination of EDC Presence and Their Endocrine Potential. Critical Reviews in Analytical Chemistry, 2015, 45, 191-200.	1.8	21
14	Role of Human UDP-Glucuronosyltransferases in the Biotransformation of the Triazoloacridinone and Imidazoacridinone Antitumor Agents C-1305 and C-1311: Highly Selective Substrates for UGT1A10. Drug Metabolism and Disposition, 2012, 40, 1736-1743.	1.7	20
15	Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells. Xenobiotica, 2011, 41, 1044-1055.	0.5	19
16	Design, synthesis and high antitumor potential of new unsymmetrical bisacridine derivatives towards human solid tumors, specifically pancreatic cancers and their unique ability to stabilize DNA G-quadruplexes. European Journal of Medicinal Chemistry, 2020, 204, 112599.	2.6	19
17	Metabolic transformations of antitumor imidazoacridinone, C-1311, with microsomal fractions of rat and human liver.. Acta Biochimica Polonica, 2007, 54, 831-838.	0.3	19
18	Relationship between volatile organohalogen compounds in drinking water and human urine in Poland. Chemosphere, 2003, 53, 899-909.	4.2	16

#	Article	IF	Citations
19	Binary Mixtures of Selected Bisphenols in the Environment: Their Toxicity in Relationship to Individual Constituents. Molecules, 2018, 23, 3226.	1.7	16
20	C-1311. Drugs of the Future, 1998, 23, 702.	0.0	16
21	Stable nanoconjugates of transferrin with alloyed quaternary nanocrystals Agâ€“Inâ€“Znâ€“S as a biological entity for tumor recognition. Nanoscale, 2018, 10, 1286-1296.	2.8	15
22	Metabolic Transformation of Antitumor Acridinone C-1305 but Not C-1311 via Selective Cellular Expression of UGT1A10 Increases Cytotoxic Response: Implications for Clinical Use. Drug Metabolism and Disposition, 2013, 41, 414-421.	1.7	14
23	Volatile organohalogen compounds in human urine: The effect of environmental exposure. Chemosphere, 2006, 62, 626-640.	4.2	13
24	Interactions of Dissolved dsDNA with Intercalating Drug by Anodic Voltammetry and Spectroscopy. Influence of pH. Electroanalysis, 2009, 21, 52-60.	1.5	13
25	Modulation of CYP3A4 activity and induction of apoptosis, necrosis and senescence by the antiâ€tumour imidazoacridinone Câ€1311 in human hepatoma cells. Cell Biology International, 2013, 37, 109-120.	1.4	13
26	Electrochemical oxidation of antitumor imidazoacridinone derivatives and the reference 2-hydroxyacridinone. Journal of Electroanalytical Chemistry, 1997, 427, 71-78.	1.9	12
27	Synthesis and cytotoxic activity of aziridinyl-1,4-naphthoquinones and naphthazarins. European Journal of Medicinal Chemistry, 1988, 23, 91-96.	2.6	11
28	Influence of temperature and interactions with ligands on dissociation of dsDNA and ligandâ€“dsDNA complexes of various types of binding. An electrochemical study. Physical Chemistry Chemical Physics, 2012, 14, 3408.	1.3	11
29	Electroanalytical and acidâ€“base properties of imidazoacridinone, an antitumor drug (C-1311). Analytica Chimica Acta, 1999, 379, 209-215.	2.6	10
30	Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells. Biochemical Pharmacology, 2012, 84, 30-42.	2.0	10
31	Electrochemical simulation of metabolism for antitumor-active imidazoacridinone C-1311 and in silico prediction of drug metabolic reactions. Journal of Pharmaceutical and Biomedical Analysis, 2019, 169, 269-278.	1.4	10
32	Electrochemical formation of the adduct between antitumor agent C-1311 and DNA nucleoside dG. Electrochemistry Communications, 2003, 5, 770-775.	2.3	9
33	Electrooxidation of dissolved dsDNA backed by in situ UVâ€“Vis spectroscopy. Bioelectrochemistry, 2007, 70, 440-445.	2.4	9
34	CYP3A4â€dependent cellular response does not relate to CYP3A4â€catalysed metabolites of Câ€1748 and Câ€1305 acridine antitumor agents in HepG2 cells. Cell Biology International, 2014, 38, 1291-1303.	1.4	9
35	Novel Resveratrol-Based Substrates for Human Hepatic, Renal, and Intestinal UDP-Glucuronosyltransferases. Chemical Research in Toxicology, 2014, 27, 536-545.	1.7	9
36	Phase I and phase II metabolism simulation of antitumor-active 2-hydroxyacridinone with electrochemistry coupled on-line with mass spectrometry. Xenobiotica, 2019, 49, 922-934.	0.5	9

#	Article	IF	Citations
37	The relevance of enzymatic oxidation by horseradish peroxidase to antitumour potency of imidazoacridinone derivatives. Chemico-Biological Interactions, 1998, 115, 1-22.	1.7	8
38	The products of electro- and photochemical oxidation of 2-hydroxyacridinone, the reference compound of antitumor imidazoacridinone derivatives. Journal of Electroanalytical Chemistry, 2002, 521, 144-154.	1.9	7
39	CYP3A4 overexpression enhances apoptosis induced by anticancer agent imidazoacridinone C-1311, but does not change the metabolism of C-1311 in CHO cells. Acta Pharmacologica Sinica, 2014, 35, 98-112.	2.8	7
40	Novel insights into conjugation of antitumor-active unsymmetrical bisacridine C-2028 with glutathione: Characteristics of non-enzymatic and glutathione S-transferase-mediated reactions. Journal of Pharmaceutical Analysis, 2021, 11, 791-798.	2.4	7
41	The overexpression of CPR and P450 3A4 in pancreatic cancer cells changes the metabolic profile and increases the cytotoxicity and pro-apoptotic activity of acridine antitumor agent, C-1748. Biochemical Pharmacology, 2017, 142, 21-38.	2.0	7
42	Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305. Xenobiotica, 2016, 46, 1056-1065.	0.5	6
43	Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes. Pharmacological Reports, 2016, 68, 663-670.	1.5	6
44	Enhanced Activity of P4503A4 and UGT1A10 Induced by Acridinone Derivatives C-1305 and C-1311 in MCF-7 and HCT116 Cancer Cells: Consequences for the Drugsâ€™ Cytotoxicity, Metabolism and Cellular Response. International Journal of Molecular Sciences, 2020, 21, 3954.	1.8	6
45	Electrochemical and in silico approaches for liver metabolic oxidation of antitumor-active triazoloacridinone C-1305. Journal of Pharmaceutical Analysis, 2020, 10, 376-384.	2.4	6
46	Metabolic Profiles of New Unsymmetrical Bisacridine Antitumor Agents in Electrochemical and Enzymatic Noncellular Systems and in Tumor Cells. Pharmaceuticals, 2021, 14, 317.	1.7	6
47	Similarity between enzymatic and electrochemical oxidation of 2-hydroxyacridinone, the reference compound of antitumor imidazoacridinones.. Acta Biochimica Polonica, 2003, 50, 515-525.	0.3	6
48	New generation of analytical tests based on the assessment of enzymatic and nuclear receptor activity changes induced by environmental pollutants. TrAC - Trends in Analytical Chemistry, 2015, 74, 109-119.	5.8	5
49	Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7. Pharmacological Reports, 2018, 70, 972-980.	1.5	5
50	Anticancer Imidazoacridinone C-1311 is Effective in Androgen-Dependent and Androgen-Independent Prostate Cancer Cells. Biomedicines, 2020, 8, 292.	1.4	5
51	Acidâ€“Base Equilibrium and Self-Association in Relation to High Antitumor Activity of Selected Unsymmetrical Bisacridines Established by Extensive Chemometric Analysis. Molecules, 2022, 27, 3995.	1.7	5
52	Endocrine Disrupting Compounds â€“ Problems and Challenges. , 2015, , .		4
53	Analysis and Bioanalysis: an Effective Tool for Data Collection of Environmental Conditions and Processes. Polish Journal of Environmental Studies, 2016, 25, 45-53.	0.6	4
54	Spectroelectroanalytical Properties of Antitumor Agent C-1311. Electroanalysis, 2007, 19, 214-219.	1.5	3

#	Article	IF	Citations
55	Modulation of UDP-glucuronidation by acridinone antitumor agents C-1305 and C-1311 in HepG2 and HT29 cell lines, despite slight impact in noncellular systems. Pharmacological Reports, 2018, 70, 470-475.	1.5	3
56	Electrochemical simulation of metabolic reduction and conjugation reactions of unsymmetrical bisacridine antitumor agents, C-2028 and C-2053. Journal of Pharmaceutical and Biomedical Analysis, 2021, 197, 113970.	1.4	3
57	Metabolic transformations of antitumor imidazoacridinone, C-1311, with microsomal fractions of rat and human liver. Acta Biochimica Polonica, 2007, 54, 831-8.	0.3	3
58	The synthesis and antitumor activity of N-glycosyl derivatives of daunorubicin.. Journal of Antibiotics, 1984, 37, 1213-1216.	1.0	1
59	Chiral Pyrazolo[4,3-e][1,2,4]triazine Sulfonamidesâ€"Their Biological Activity, Lipophilicity, Protein Affinity, and Metabolic Transformations. Applied Sciences (Switzerland), 2021, 11, 2660.	1.3	1
60	65 Phase II drug metabolism UGT1A enzyme affects cellular response of colon cancer cells to antitumor triazoloacridinone C-1305 treatment. European Journal of Cancer, 2014, 50, 26.	1.3	0
61	67 Cytotoxic response as a result of the cross-talk between UGT mediated metabolism and modulation of UGT activity by C-1311 and C-1305 acridinone antitumor agents in selected solid tumor cell lines. European Journal of Cancer, 2014, 50, 27.	1.3	0
62	Detoxification of the tricyclic antidepressant opipramol and its analog â€“ IS-noh by UGT enzymes before and after activation by phase I enzymes in rat liver microsomes. Chemical Papers, 2021, 75, 4973.	1.0	0
63	Glucuronides of antitumor agents Câ€‘1311 and Câ€‘1305 modulate cytotoxicity in cancer cells. FASEB Journal, 2012, 26, 966.2.	0.2	0